July 23, 2014 5:11 AM ET

Biotechnology

Company Overview of Palatin Technologies Inc.

Company Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of diseases. Its clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that is in Phase III clinical trials for the treatment of female sexual dysfunction. The company’s drug development programs comprise PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase 1 clinical trial for the treatment of cardiovascular and pulmonary indications; melanocortin receptor-based compounds for treatment of obesity; and Melanocortin receptor-1 agonist peptides for treatment of dermatologic and inflammatory disease indications. Palatin Technol...

4B Cedar Brook Drive

Cedar Brook Corporate Center

Cranbury, NJ 08512

United States

Founded in 1986

20 Employees

Phone:

609-495-2200

Fax:

609-495-2201

Key Executives for Palatin Technologies Inc.

Co-Founder
Age: 52
Total Annual Compensation: $436.8K
Chief Financial Officer
Age: 57
Total Annual Compensation: $394.2K
Compensation as of Fiscal Year 2013.

Palatin Technologies Inc. Key Developments

Palatin Technologies Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2014

Palatin Technologies Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2014. For the quarter, the company reported loss from operations was of $3,363,738 compared to $4,023,784 for the same period a year ago. Loss before income taxes were $3,359,557 compared to $4,015,258 for the same period a year ago. Net loss was $1,512,911 or $0.01 per and diluted share compared to $4,015,258 or $0.04 per basic and diluted share for the same period a year ago. The decrease in net loss for the quarter ended March 31, 2014, compared to the same period last fiscal year, is primarily attributable to the recognition of $1.85 million in tax benefits in the quarter ended March 31, 2014. For nine months, the company reported loss from operations was of $11,466,826 compared to $10,865,060 for the same period a year ago. Loss before income taxes were $11,455,200 compared to $17,897,334 for the same period a year ago. Net loss was $9,608,554 or $0.09 per and diluted share compared to $16,144,126 or $0.17 per basic and diluted share for the same period a year ago.

Palatin Technologies Inc. to Report Q3, 2014 Results on May 13, 2014

Palatin Technologies Inc. announced that they will report Q3, 2014 results at 7:30 AM, US Eastern Standard Time on May 13, 2014

Palatin Technologies Inc., Q3 2014 Earnings Call, May 13, 2014

Palatin Technologies Inc., Q3 2014 Earnings Call, May 13, 2014

Similar Private Companies By Industry

Company Name Region
miRagen Therapeutics, Inc. United States
Velcera Inc. United States
Genetic Immunity, LLC United States
MyGene International Inc. United States
Carta Proteomics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Palatin Technologies Inc., please visit www.palatin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.